Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Lancet. HIV|August 9, 2020
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort studySergio Serrano-Villar, Javier Martínez-Sanz, Raquel Ron, et al.
BMC Infectious Diseases|May 4, 2023
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analysesRodrigo Alonso-Navarro, Margarita Ramírez, Mar Masiá, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|May 12, 2024
Prospective study for the early detection of lung carcinoma in patients with HIV infection (GESIDA study 8815)M Eulalia Valencia, Tatiana Pirogova, Delia Romera, et al.
BMC Infectious Diseases|April 11, 2025
Remdesivir associated with reduced mortality in hospitalized COVID-19 patients: treatment effectiveness using real-world data and natural language processingJosé Ramón Arribas López, María Pilar Ruiz Seco, Francisco Fanjul, et al.
The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale|August 23, 2021
Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on AdmissionMercedes García-Gasalla, Juana M Ferrer, Pablo A Fraile-Ribot, et al.
HIV Medicine|March 29, 2023
Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohortJorge Palacio-Vieira, Sergio Moreno-Fornés, Yesika Díaz, et al.
Open Forum Infectious Diseases|April 1, 2024
Evolving AIDS- and non-AIDS Mortality and Predictors in the PISCIS Cohort of People Living With HIV in Catalonia and the Balearic Islands (Spain), 1998-2020Daniel K Nomah, Suju Jamarkattel, Andreu Bruguera, et al.
International Journal of STD & AIDS|August 15, 2024
Developing and validating a clinical risk score to predict losses in the PISCIS cohort of people with HIVJorge Palacio-Vieira, Yesika Díaz, Sergio Moreno-Fornés, et al.
HIV Medicine|October 21, 2025
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohortJesús Troya, María Luisa Montes, María José Galindo, et al.
AIDS (London, England)|March 10, 2026
Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohortJesús Troya, María Luisa Montes, María José Galindo, et al.
Pageof 3